Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AMLVania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens
5 April 2024
Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical studyMyeong Geun Choi, Gun Woo Son, Mi Young Choi, Jae Seob Jung, Jin Kyung Rho, Wonjun Ji, Byeong Gon Yoon, Jong-Min Jo, Yong Man Kim, Dae-Hyun Ko, Jae Cheol Lee, Chang-Min Choi
27 March 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John HaanenSee the full list of authors
26 March 2024
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1Annelisa M. Cornel, Loutje van der Sman, Jip T van Dinter, Marta Arrabito, Ester Dunnebach, Marliek van Hoesel, Thomas A Kluiver, Ana P Lopes, Noël M M Dautzenberg, Linde Dekker, Jorik M van Rijn, Denise A M H van den Beemt, Juliane L Buhl, Aimee du Chatinier, Farnaz BarnehSee the full list of authors
21 March 2024
Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG miceShahryar Khoshtinat Nikkhoi, Ge Yang, Hajar Owji, Mayara Grizotte-Lake, Rick I Cohen, Lazaro Gil Gonzalez, Mohammad Massumi, Arash Hatefi
15 March 2024
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulationJiri Eitler, Wiebke Rackwitz, Natalie Wotschel, Venugopal Gudipati, Nivedha Murali Shankar, Anastasia Sidorenkova, Johannes B Huppa, Paola Ortiz-Montero, Corinna Opitz, Stephan R Künzel, Susanne Michen, Achim Temme, Liliana Rodrigues Loureiro, Anja Feldmann, Michael BachmannSee the full list of authors
27 February 2024
Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasisSarah L Ash, Rebecca Orha, Holly Mole, Meg Dinesh-Kumar, Steven P Lee, Frances K Turrell, Clare M Isacke
27 February 2024
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapyStephanie N Shishido, Olivia Hart, Sujin Jeong, Aidan Moriarty, Darren Heeke, John Rossi, Adrian Bot, Peter Kuhn
12 February 2024
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicityTamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Ekram A Gad, Carla A Jaeger-Ruckstuhl, Sylvain Simon, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman, Stanley R Riddell
7 February 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, Scott Kopetz, Michael J Overman, Milind Javle, Mara B Antonoff, Ching-Wei D Tzeng, Robert A Wolff, Shubham Pant, Kathryn Lito, Kelly Rangel, Bryan Fellman, Ying Yuan, Karen H LuSee the full list of authors
2 February 2024
